In a recent study published in Nature Communications , researchers investigated the potential therapeutic benefits of semaglutide for alcohol use disorders (AUDs). AUDs are a global health problem, but current treatment options are limited. The discovery of novel drugs to treat AUD is crucial, given recent evidence of reduced alcohol intake in individuals prescribed glucagon-like peptide-1 receptor agonist (GLP-1RA) drugs for type 2 diabetes or obesity.
Semaglutide is a GLP-1 receptor agonist authorized for diabetes type 2 treatment in the year 2017 and reducing adiposity in 2021 and has been found to reduce alcohol consumption and relapse in rats. However, research on the therapeutic advantages of semaglutide in preventing and treating AUD in the real world remains inadequate. In the present multicentre study, researchers investigated the relationship between semaglutide and AUD occurrence and recurrence in obese individuals.
They then evaluated the repeatability of the study findings among type 2 diabetes patients from different periods. The team compared type 2 diabetes patients with adiposity (33%) and diabetics who were not obese (67%) with obese patients diagnosed with type 2 diabetes (40%) and individuals with obesity but no diabetes diagnosis (60%), to investigate potential interactions of semaglutide use effects among individuals with the two comorbidities.i The outcomes were assessed independently by age, gender, and race.
Researchers analyzed the electronic medical.